Literature DB >> 12352619

The -174 G/C polymorphism of the interleukin-6 gene promoter is associated with Alzheimer's disease in an Italian population [corrected].

Roberto Pola1, Andrea Flex, Eleonora Gaetani, Antonio Dal Lago, Laura Gerardino, Paolo Pola, Roberto Bernabei.   

Abstract

Interleukin-6 (IL-6) is a multifunctional cytokine playing a crucial role in inflammation and tissue injury. A role for this molecule in neurodegeneration and Alzheimer's disease (AD) has been proposed. The aim of this study was to evaluate the association between a common polymorphism of the IL-6 gene promoter and AD in the Italian population. We found that the frequency of the GG genotype was significantly higher in AD patients than controls on both univariate ( rho< 0.0001) and multivariate analysis ( rho< 0.0001). In contrast, the CC genotype seems to be associated with a reduced risk of disease ( rho< 0.0001). Our data indicate that the IL-6 gene polymorphism is associated with AD in Italians and confirm that IL-6 is crucial in the pathophysiology of neurodegenerative disorders.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12352619     DOI: 10.1097/00001756-200209160-00015

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  12 in total

1.  Interaction between interleukin-6 and intercellular adhesion molecule-1 genes and Alzheimer's disease risk.

Authors:  Onofre Combarros; Jon Infante; Javier Llorca; Nicolás Peña; Carlos Fernández-Viadero; José Berciano
Journal:  J Neurol       Date:  2005-03-22       Impact factor: 4.849

2.  Interaction between dopamine beta-hydroxylase and interleukin genes increases Alzheimer's disease risk.

Authors:  I Mateo; J Infante; E Rodríguez; J Berciano; O Combarros; J Llorca
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-02       Impact factor: 10.154

3.  Gene-gene interaction between CARD8 and interleukin-6 reduces Alzheimer's disease risk.

Authors:  Ana Fontalba; Olga Gutiérrez; Javier Llorca; Ignacio Mateo; José Luis Vázquez-Higuera; José Berciano; José Luis Fernández-Luna; Onofre Combarros
Journal:  J Neurol       Date:  2009-03-01       Impact factor: 4.849

4.  The interleukin-6 gene -174G>C and -572G>C promoter polymorphisms are related to cerebral aneurysms.

Authors:  L Morgan; J Cooper; H Montgomery; N Kitchen; S E Humphries
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-04-28       Impact factor: 10.154

Review 5.  Association between polymorphism in the promoter region of Interleukin 6 (-174 G/C) and risk of Alzheimer's disease: a meta-analysis.

Authors:  Limeng Dai; Dan Liu; Hong Guo; Yanyan Wang; Yun Bai
Journal:  J Neurol       Date:  2011-07-12       Impact factor: 4.849

6.  Association between interleukin-6 gene promoter -572C/G polymorphism and the risk of sporadic Alzheimer's disease.

Authors:  Mei-xia He; Wan-li Yang; Ming-ming Zhang; Ya-jun Lian; Hai-ying Hua; Jin-sheng Zeng; Li-rong Zhang
Journal:  Neurol Sci       Date:  2009-12-03       Impact factor: 3.307

Review 7.  Inflammatory Cytokines and Alzheimer's Disease: A Review from the Perspective of Genetic Polymorphisms.

Authors:  Fan Su; Feng Bai; Zhijun Zhang
Journal:  Neurosci Bull       Date:  2016-08-27       Impact factor: 5.203

8.  The -174 G/C polymorphism in interleukin-6 (IL-6) promoter region is associated with serum IL-6 and carcinoembryonic antigen levels in patients with colorectal cancers in Taiwan.

Authors:  Kun-Yun Yeh; Ying-Ying Li; Ling-Ling Hsieh; Jim-Ray Chen; Rei-Ping Tang
Journal:  J Clin Immunol       Date:  2009-08-29       Impact factor: 8.317

9.  IL-6-174 G/C and -572 C/G polymorphisms and risk of Alzheimer's disease.

Authors:  Hui-Ping Qi; Zheng-Yi Qu; Shu-Rong Duan; Shu-Qin Wei; Shi-Rong Wen; Sheng Bi
Journal:  PLoS One       Date:  2012-06-06       Impact factor: 3.240

10.  +874(T-->A) single nucleotide gene polymorphism does not represent a risk factor for Alzheimer's disease.

Authors:  Lorenza Galimberti; Beatrice Arosio; Carmen Calabresi; Silvia Scurati; Susanna Hamilton; Simona Delli Carpini; Carlo Vergani; Giorgio Annoni
Journal:  Immun Ageing       Date:  2004-11-12       Impact factor: 6.400

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.